Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.52 CAD -1.54% Market Closed
Market Cap: 135.8m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Gross Margin
Biosyent Inc

79.8%
Current
80%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.8%
=
Gross Profit
27m
/
Revenue
33.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CA
Biosyent Inc
XTSX:RX
133.5m CAD
80%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-3%
US
Eli Lilly and Co
NYSE:LLY
749.7B USD
81%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK
85%
US
Johnson & Johnson
NYSE:JNJ
372B USD
69%
US
Merck & Co Inc
NYSE:MRK
257.3B USD
77%
CH
Roche Holding AG
SIX:ROG
201.7B CHF
73%
UK
AstraZeneca PLC
LSE:AZN
163B GBP
82%
CH
Novartis AG
SIX:NOVN
179.6B CHF
75%
US
Pfizer Inc
NYSE:PFE
146B USD
71%
Country CA
Market Cap 133.5m CAD
Gross Margin
80%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 749.7B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 372B USD
Gross Margin
69%
Country US
Market Cap 257.3B USD
Gross Margin
77%
Country CH
Market Cap 201.7B CHF
Gross Margin
73%
Country UK
Market Cap 163B GBP
Gross Margin
82%
Country CH
Market Cap 179.6B CHF
Gross Margin
75%
Country US
Market Cap 146B USD
Gross Margin
71%
No Stocks Found

Biosyent Inc
Glance View

Market Cap
133.5m CAD
Industry
Pharmaceuticals

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

RX Intrinsic Value
9.62 CAD
Overvaluation 17%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
79.8%
=
Gross Profit
27m
/
Revenue
33.8m
What is the Gross Margin of Biosyent Inc?

Based on Biosyent Inc's most recent financial statements, the company has Gross Margin of 79.8%.